BACE-1 is expressed in the blood-brain barrier endothelium and is upregulated in a murine model of Alzheimer's disease

Journal of Cerebral Blood Flow and Metabolism

Volumn 36, Issue 7, 2016, Pages 1281-1294

  Devraj, Kavi ^a   Poznanovic, Slobodan ^b   Spahn, Christoph ^c   Schwall, Gerhard ^b   Harter, Patrick N ^a   Mittelbronn, Michel ^a   Antoniello, Katia ^d   Paganetti, Paolo ^d   Muhs, Andreas ^d   Heilemann, Mike ^c   Hawkins, Richard A ^e   Schrattenholz, André ^f   Liebner, Stefan ^a  

^a GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

^b ORGenTec Diagnostika GmbH   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d AC IMMUNE SA   (Switzerland)

^e ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^f Pivot GmbH   (Germany)

Author keywords

Alzheimer's disease; BACE 1; blood brain barrier; endothelium; amyloid

Indexed keywords

AMYLOID BETA PROTEIN; BACE 1 PROTEIN; PROTEINASE; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN; ASPARTIC PROTEINASE; BACE1 PROTEIN, MOUSE; SECRETASE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BOVINE; BRAIN CAPILLARY ENDOTHELIUM; CELL FRACTIONATION; CELL ISOLATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UPREGULATION; ANIMAL; C57BL MOUSE; CELL CULTURE; DISEASE MODEL; ENDOTHELIUM CELL; GENETICS; METABOLISM; PRIMARY CELL CULTURE; REAL TIME POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; CATTLE; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOHISTOCHEMISTRY; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROVESSELS; PRIMARY CELL CULTURE; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84976902836     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1177/0271678X15606463     Document Type: Article

References (41)

1. Probst G, and Xu Y-Z. Small-molecule BACE1 inhibitors: a patent literature review (2006-2011). Expert Opin Ther Pat 2012; 22: 511-540
2. Revesz T, Holton JL, Lashley T, et al. Genetics, and molecular pathogenesis of sporadic, and hereditary cerebral amyloid angiopathies. Acta Neuropathol 2009; 118: 115-130
3. Bush AI, Martins RN, Rumble B, et al. The amyloid precursor protein of Alzheimer's disease is released by human platelets. J Biol Chem 1990; 265: 15977-15983
4. Bush AI, Beyreuther K, and Masters CL. The beta A4 amyloid protein precursor in human circulation. Ann N Y Acad Sci 1993; 695: 175-182
5. Ho L, Fukuchi KI, and Younkin SG. The alternatively spliced Kunitz protease inhibitor domain alters amyloid beta protein precursor processing, and amyloid beta protein production in cultured cells. J Biol Chem 1996; 271: 30929-30934
6. Moir RD, Lynch T, Bush AI, et al. Relative increase in Alzheimer's disease of soluble forms of cerebral Ab amyloid protein precursor containing the Kunitz protease inhibitory domain. J Biol Chem 1998; 273: 5013-5019
7. Tamagno E, Guglielmotto M, Monteleone D, et al. Amyloid-b production: major link between oxidative stress, and BACE1. Neurotox Res 2012; 22: 208-219
8. Kandalepas PC, and Vassar R. Identification, and biology of b-secretase. J Neurochem 2012; 120(Suppl 1): 55-61
9. Ohno M, Sametsky EA, Younkin LH, et al. BACE1 deficiency rescues memory deficits, and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 2004; 41: 27-33
10. Klaver DW, Wilce MCJ, Cui H, et al. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease?. Current strategies, and future directions. Biol Chem 2010; 391: 849-859
11. May PC, Dean RA, Lowe SL, et al. Robust central reduction of amyloid-b in humans with an orally available, non-peptidic b-secretase inhibitor. J Neurosci 2011; 31: 16507-16516
12. Fleck D, Garratt AN, Haass C, et al. BACE1 dependent neuregulin processing: review. Curr Alzheimer Res 2012; 9: 178-183
13. Huth T, and Alzheimer C. Voltage-dependent Naθ channels as targets of BACE1 - implications for neuronal firing, and beyond. Curr Alzheimer Res 2012; 9: 184-188
14. Venugopal C, Demos CM, Rao KSJ, et al. Betasecretase: structure, function, and evolution. CNS Neurol Disord Drug Targets 2008; 7: 278-294
15. Zü chner T, Perez-Polo JR, and Schliebs R. Beta-secretase BACE1 is differentially controlled through muscarinic acetylcholine receptor signaling. J Neurosci Res 2004; 77: 250-257
16. Rockenstein E, Mallory M, Mante M, et al. Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42). J Neurosci Res 2001; 66: 573-582
17. Fisher J, Devraj K, Ingram J, et al. Ferritin: a novel mechanism for delivery of iron to the brain, and other organs. Am J Physiol, Cell Physiol 2007; 293: C641-649
18. Liebner S, and Corada M. Wnt/b-catenin signaling controls development of the blood-brain barrier. J Cell Biol 2008; 183: 409-417
19. Czupalla CJ, Liebner S, and Devraj K. In vitro models of the blood-brain barrier. Methods Mol Biol 2014; 1135: 415-437
20. Sánchez del Pino MM, Hawkins RA, and Peterson DR. Biochemical discrimination between luminal, and abluminal enzyme, and transport activities of the blood-brain barrier. J Biol Chem 1995; 270: 14907-14912
21. Devraj K, Klinger ME, Myers RL, et al. GLUT-1 glucose transporters in the blood-brain barrier: differential phosphorylation. J Neurosci Res 2011; 89: 1913-1925
22. Spahn C, Cella-Zannacchi F, Endesfelder U, et al. Correlative super-resolution imaging of RNA polymerase distribution, and dynamics, bacterial membrane, and chromosomal structure in Escherichia coli. Meth Appl Fluoresc 2015; 3: 014005
23. Mowrer KR, and Wolfe MS. Promotion of BACE1 mRNA alternative splicing reduces amyloid beta-peptide production. J Biol Chem 2008; 283: 18694-18701
24. Sankaranarayanan S, Price EA, Wu G, et al. In vivo betasecretase 1 inhibition leads to brain Abeta lowering, and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1. J Pharmacol Exp Ther 2008; 324: 957-969
25. Lyck R, Ruderisch N, Moll AG, et al. Culture-induced changes in blood-brain barrier transcriptome: implications for amino-Acid transporters in vivo. J Cereb Blood Flow Metab 2009; 29: 1491-1502
26. Simpson IA, and Davies P. Reduced glucose transporter concentrations in brains of patients with Alzheimer's disease. Ann Neurol 1994; 36: 800-801
27. Eisele YS, Obermü ller U, Heilbronner G, et al. Peripherally applied A -containing inoculates induce cerebral - amyloidosis. Science 2010; 330: 980-982
28. Cirrito JR, Deane R, Fagan AM, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloidbeta deposition in an Alzheimer disease mouse model. J Clin Invest 2005; 115: 3285-3290
29. Shibata M, Yamada S, Kumar SR, et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000; 106: 1489-1499
30. Cam JA, Zerbinatti CV, Li Y, et al. Rapid endocytosis of the low density lipoprotein receptor-related protein modulates cell surface distribution, and processing of the beta-Amyloid precursor protein. J Biol Chem 2005; 280: 15464-15470
31. Perez-Gonzalez R, Gauthier SA, Kumar A, et al. The exosome secretory pathway transports amyloid precursor protein carboxyl-Terminal fragments from the cell into the brain extracellular space. J Biol Chem 2012; 287: 43108-43115
32. Deane R, Sagare A, Hamm K, et al. IgG-Assisted agedependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci 2005; 25: 11495-11503
33. Swerdlow RH, and Khan SM. A 'mitochondrial cascade hypothesis' for sporadic Alzheimer's disease. Med Hypotheses 2003; 63: 8-20
34. Boyd-Kimball D, Sultana R, Mohmmad-Abdul H, et al. Rodent Abeta(1-42) exhibits oxidative stress properties similar to those of human Abeta(1-42): implications for proposed mechanisms of toxicity. J Alzheimers Dis 2004; 6: 515-525
35. Elhusseiny A, Cohen Z, Olivier A, et al. Functional acetylcholine muscarinic receptor subtypes in human brain microcirculation: identification, and cellular localization. J Cereb Blood Flow Metab 1999; 19: 794-802
36. Yang L-B, Lindholm K, Yan R, et al. Elevated betasecretase expression, and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 2003; 9: 3-4
37. Bodendorf U, Danner S, Fischer F, et al. Expression of human beta-secretase in the mouse brain increases the steady-state level of beta-Amyloid. J Neurochem 2002; 80: 799-806
38. Roberds SL, Anderson J, Basi G, et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 2001; 10: 1317-1324
39. Ghosh AK, Brindisi M, and Tang J. Developing b-secretase inhibitors for treatment of Alzheimer's disease. J Neurochem 2011; 120(Suppl 1): 71-83
40. Yu YJ, Zhang Y, Kenrick M, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 2011; 3: 84ra44
41. Simpson IA, Ponnuru P, Klinger ME, et al. A novel model for brain iron uptake: introducing the concept of regulation. J Cereb Blood Flow Metab 2015; 35: 48-57